Xbrane Biopharma AB (XBRANE.ST)

Nasdaq Stockholm · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), Xbrane Biopharma AB reported revenue of SEK 198.7M and net income of −SEK 266.2M. Annual financial statements are available for fiscal years 2020 to 2024, taken from the company's ESEF annual reports (IFRS).

Open interactive financials →

Key financials

SEK	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31	FY2020 2020-12-31
Income statement
Revenue	SEK 198.7M	SEK 238.7M	SEK 57.6M	SEK 10.7M	–
Gross profit	SEK 180.5M	SEK 35.4M	SEK 57.6M	SEK 10.7M	–
Operating income	−SEK 217.9M	−SEK 322.2M	−SEK 166.2M	−SEK 180.6M	−SEK 217.4M
Net income	−SEK 266.2M	−SEK 388.2M	−SEK 172.5M	−SEK 188.4M	−SEK 226.0M
Diluted EPS	−SEK 0.22	−SEK 0.66	−SEK 0.32	−SEK 0.38	−SEK 0.59
Cash flow
Operating cash flow	−SEK 133.7M	−SEK 406.7M	−SEK 193.9M	−SEK 219.6M	−SEK 238.4M
Capital expenditure	SEK 501.0K	SEK 6.8M	SEK 11.6M	SEK 27.7M	SEK 3.9M
Free cash flow	−SEK 134.2M	−SEK 413.5M	−SEK 205.5M	−SEK 247.3M	−SEK 242.3M
Balance sheet
Cash and equivalents	SEK 124.3M	SEK 65.4M	SEK 194.0M	SEK 295.2M	SEK 243.1M
Total assets	SEK 842.4M	SEK 653.5M	SEK 690.5M	SEK 688.4M	SEK 463.8M
Total liabilities	SEK 633.9M	SEK 482.2M	SEK 265.6M	SEK 256.7M	SEK 206.1M
Total debt	SEK 66.4M	SEK 62.5M	SEK 0	–	–
Shareholders' equity	SEK 208.5M	SEK 171.3M	SEK 424.9M	SEK 431.7M	SEK 257.7M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full XBRANE.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open XBRANE.ST financials →